According to the official website of the National Health Commission, according to the approval opinions of the State Food and Drug Administration on the conditional approval of the marketing application for the combined packaging of novel coronavirus tablets/ritonavir tablets and the marketing application of deuterium rimidovir hydrobromide tablets, in order to further improve the antiviral treatment scheme for novel coronavirus infection, the two drugs were included in the Diagnosis and Treatment Scheme for novel coronavirus Infection (Tenth Edition for Trial Implementation). It is reported that the combined packaging of Centrotevir Tablets/Litonavir Tablets is used to treat adult patients with mild and moderate novel coronavirus infection (COVID-19). It should be used as soon as possible within 3 days after symptoms appear. Deuteromidevir hydrobromide tablet is used to treat adult patients with mild to moderate novel coronavirus infection (COVID-19). It should be used as soon as possible within 3 days after symptoms appear. Before using the above two drugs, carefully read the instructions approved by the State Food and Drug Administration, and use the drugs correctly according to the indications, usage and dosage specified in the instructions. Before prescribing drugs, doctors should be familiar with contraindications, adverse reactions, drug interactions and other information, and ask patients about drug allergy history and other information in detail, so as to avoid the use of patients with contraindications, and avoid the use of drugs that are forbidden to be used in combination. (Xinhua News Agency)